ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Changchun GeneScience Pharmaceutical and Par Health side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Changchun GeneScience PharmaceuticalPar Health
studies on the registry11241
open to participants now470
phase 3 studies under way110
reach primary completion within a year180
programswith a study of their own in two years30none read

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseChangchun GeneScience PharmaceuticalPar Health
Phase 1

Changchun GeneScience Pharmaceutical: 18 of its 30 programs at phase 1

  1. GENSCI098phase 1
  2. GENSCI142phase 1
  3. PEG-rhGH with new preparation (T)phase 1
  4. PEG-rhGH with present preparation (T)phase 1
  5. GENSCI128phase 1

and 13 more — sign in to see them all

60%
–
Phase 2

Changchun GeneScience Pharmaceutical: 7 of its 30 programs at phase 2

  1. GENSCI048phase 2
  2. GENSCI134phase 2
  3. GS1-144phase 2
  4. GENSCI120phase 2
  5. GENSCI136phase 2

and 2 more — sign in to see them all

23%
–
Phase 3

Changchun GeneScience Pharmaceutical: 3 of its 30 programs at phase 3

  1. Cabergolinephase 3
  2. PEG-hGH Injectionphase 3
  3. leuprolide mesylatephase 3
10%
–
Approved, new studies

Changchun GeneScience Pharmaceutical: 2 of its 30 programs at approved, new studies

  1. Megestrol Acetateapproved, new study
  2. Human Growth Hormoneapproved, new study
7%
–

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Changchun GeneScience Pharmaceutical13 readouts · 3 phase 3

Changchun GeneScience Pharmaceutical, Nov ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Cabergolinephase 3 · Nov 21 · NCT07124221
  2. GENSCI134phase 2 · Nov 25 · NCT07016802

Changchun GeneScience Pharmaceutical, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. polyethylene glycol-recombinant human growth hormonephase 2 · Dec 23 · NCT07260500
  2. Megestrol Acetateapproved, new study · Dec 31 · NCT07243379

Changchun GeneScience Pharmaceutical, Jan ’27: 2 programs whose next study reaches primary completion

  1. GENSCI142phase 1 · Jan 5 · NCT07663838
  2. GS1-144phase 2 · Jan 31 · NCT07491289

Changchun GeneScience Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. GENSCI136phase 2 · Feb 7 · NCT07366866
·

Changchun GeneScience Pharmaceutical, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. GENSCI155phase 1 · Apr 16 · NCT07638800
  2. Human Growth Hormoneapproved, new study · Apr 28 · NCT07691125

Changchun GeneScience Pharmaceutical, May ’27: 1 program whose next study reaches primary completion

  1. GENSCI161phase 1 · May 6 · NCT07476586
···

Changchun GeneScience Pharmaceutical, Sep ’27: 2 programs whose next study reaches primary completion

  1. GENSCI120phase 2 · Sep 0 · NCT07423533
  2. GENSCI098phase 1 · Sep 2 · NCT06569758

Changchun GeneScience Pharmaceutical, Oct ’27: 1 program whose next study reaches primary completion

  1. GENSCI164phase 1 · Oct 25 · NCT07790783
Par Health0 readouts · 0 phase 3············
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Changchun GeneScience Pharmaceutical

New programs 2

Reached a new phase 1

  • GENSCI136phase 2 · Oct 27 · Autoimmune Diseases

Study stopped 1

  • GENSCI122phase 1 · terminated Nov 17 · none of its studies left running“The sponsor adjusted its research and development strategy” · NCT06772415

Primary completion later 0

None

Par Health

No programs read for this company.

Where they overlap

No condition where two of them both have programs.

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Changchun GeneScience Pharmaceutical 7 of 30 · Par Health 0 of 0 programs (7 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.